Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05942300 · ClinicalTrials.gov registry record · Phase 1

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

A Phase 1 study of Recurrent Ovarian Cancer, sponsored by Lan Coffman.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05942300 is a Phase 1 study of Recurrent Ovarian Cancer that is actively recruiting participants, run by Lan Coffman. The registered enrollment target is 30 participants, below the 186-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05942300, a Phase 1 study of Recurrent Ovarian Cancer, is actively recruiting participants, sponsored by Lan Coffman.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.

Conditions Studied

Recurrent Ovarian Cancer

Interventions

  • DRUG carboplatin
  • DRUG CPI-0209

Study Locations (1)

Pennsylvania

  • Magee-Womens Research Institute / UPMC Magee Womens Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-01-30
Est. Completion 2028-12-31
Phase Phase 1

Sponsor

Lan Coffman

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05942300

The ClinicalTrials.gov registry entry for NCT05942300 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Lan Coffman, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.

NCT05942300 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05942300 about?

NCT05942300 is a clinical study titled "CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer". This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.

What is the current status of trial NCT05942300?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-01-30. Estimated completion is 2028-12-31.

What conditions does trial NCT05942300 study?

This clinical trial studies the following conditions: Recurrent Ovarian Cancer.

What interventions are being tested in trial NCT05942300?

The interventions under investigation include: carboplatin (DRUG), CPI-0209 (DRUG).

Who is sponsoring clinical trial NCT05942300?

This trial is sponsored by Lan Coffman, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05942300 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Ovarian Cancer

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.